Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody.

PLoS pathogens - 1 Dec 2020

Wu Nicholas C, Yuan Meng, Bangaru Sandhya, Huang Deli, Zhu Xueyong, Lee Chang-Chun D, Turner Hannah L, Peng Linghang, Yang Linlin, Burton Dennis R, Nemazee David, Ward Andrew B, Wilson Ian A

Abstract excerpt

Epitopes that are conserved among SARS-like coronaviruses are attractive targets for design of cross-reactive vaccines and therapeutics. CR3022 is a SARS-CoV neutralizing antibody to a highly conserved epitope on the receptor binding domain (RBD) on the spike protein that is able to cross-react with SARS-CoV-2, but with lower affinity. Using x-ray crystallography, mutagenesis, and binding experiments, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Neutralizing
Share to Antibodies, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antigenic Variation

Share to Cross Reactions

Share to Epitopes

Share to SARS-CoV-2

Share to Severe Acute Respiratory Syndrome

Share to Severe acute respiratory syndrome-related coronavirus

Source

Open in PubMed Open full text

Identifiers

PMID: 33275640
DOI: 10.1371/journal.ppat.1009089
PMCID: PMC7744049

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody.PMID 33275640Read ↗

A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoVSemantic proximity Read ↗

Exploring the role of framework mutations in enabling breadth of a cross-reactive antibody (CR3022) against the SARS-CoV-2 RBD and its variants of concern.Semantic proximity Read ↗

Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike proteinSemantic proximity Read ↗

Uncovering a conserved vulnerability site in SARS‐CoV‐2 by a human antibodySemantic proximity Read ↗

Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variantsSemantic proximity Read ↗

Structural basis for broad coronavirus neutralizationSemantic proximity Read ↗

Conformational flexibility in neutralization of SARS-CoV-2 by naturally elicited anti-SARS-CoV-2 antibodiesSemantic proximity Read ↗

Delineating the functional activity of antibodies with cross-reactivity to SARS-CoV-2, SARS-CoV-1 and related sarbecovirusesSemantic proximity Read ↗

Delineating the functional activity of antibodies with cross-reactivity to SARS-CoV-2, SARS-CoV-1 and related sarbecovirusesSemantic proximity Read ↗

Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike TrimerSemantic proximity Read ↗

Cross neutralization of emerging SARS-CoV-2 variants of concern by antibodies targeting distinct epitopes on spikeSemantic proximity Read ↗

Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.